This year's search of 'adrenal' and 'steroidogenesis' in PubMed yielded more than 6,000 hits from which we have selected the following collection of articles. Whenever possible we have avoided subjects which have been discussed in detail in the Yearbook 2008, unless progress in the field has been incremental [1]. Some emerging themes include modulators of steroidogenesis as a cause of variant phenotypes or new monogenic disorders; peripheral circadian regulation within the adrenal itself; DHEA and adrenarche; and potential cancer therapies developed from studying the molecular pathophysiology of adrenal tumor tissues and cells.
Mechanism of the year Sulfation defects cause adrenal hyperandrogenismInactivating PAPSS2 mutations in a patient with premature pubarche Noordam C, Dhir V, McNelis JC, Schlereth F, Hanley NA, Krone N, Smeitink JA, Smeets R, Sweep FC, Grinten HL, Arlt W Centre for Endocrinology, Diabetes, and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK w.arlt@bham.ac.uk N Engl J Med 2009;360:2310-2318 Background: Dehydroepiandrosterone (DHEA) sulfotransferase, known as SULT2A1, converts the androgen precursor DHEA to its inactive sulfate ester, DHEAS. This conversion is important in preventing the DHEA being converted to more potent androgens. Normal SULT2A1 catalytic activity requires the sulfate donor, 3'-phosphoadenosine-5'-phosphosulfate (PAPS), which is generated by PAPS synthase 2 (PAPSS2). Defects in these systems could result in impaired DHEA sulfation, resulting in increased conversion of DHEA to androgens. Methods: Mutational analysis of PAPSS2 in a girl with premature pubarche, hyperandrogenic anovulation, very low DHEAS levels, and increased androgen levels. Results: Compound heterozygous mutations in the gene encoding human PAPSS2 were identified in this individual. These mutations were found to be inactivateded following coincubation of human SULT2A1 with wild-type or mutant PAPSS2 proteins. Conclusion: PAPSS2 deficiency is a novel monogenic adrenocortical cause of androgen excess.Although cytochrome P450 and hydroxysteroid dehydrogenase enzymes play a central role in classic steroidogenic pathways, it is becoming increasingly clear that many other cofactors and modulators of steroidogenic activity also play a key role in regulating this process. Disruption of some of these factors has been shown to result in human disease (e.g. P450 oxidoreductase deficiency; variations in hexose-6-phosphate dehydrogenase) [2,3]. In this recent report, Wiebke Arlt and colleagues hypothesized that the high DHEA levels and undetectable DHEAS levels found in a girl with premature pubarche, hyperandrogenism, and PCOS/secondary amenorrhea could be due to a defect in part of the sulfation pathway. Sulfation of DHEA into the inactive compound DHEAS is important in reducing circulating levels of DHEA and preventing its conversion into more potent androgens such as testosterone. Sulfation of DHEA is primarily regulated by DHEA sulfotransferase (SULT2A1) in the...